Electromedical Technologies Announces Financial and Operational Highlights for the Three and Nine Months Ended September 30, 2022 – Yahoo Finance
Electromedical Technologies Announces Financial and Operational Highlights for the Three and Nine Months Ended September 30, 2022
SCOTTSDALE, Ariz., Dec. 5, 2022 /PRNewswire/ — Electromedical Technologies, Inc. (OTC-QB: EMED) (“Electromedical” or the “Company”), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to provide its Financial and Operational Highlights for the three and nine months ended September 30, 2022.
Electromedical Founder and CEO, Matthew Wolfson, remarked, “Topline revenue growth of 24% over the June 2022 quarter and a sharply narrowed net loss so far this year highlight steady financial improvements, while we expand our sales and marketing infrastructure ahead of the expected 2023 launch of our new market leading flagship device, the WellnessPro Infinity™.”
Highlights for the three and nine months ended Sep 30, 2022
Strong net sales during the quarter totaling approximately $280,000, beating both Q1 and Q2 2022 sales. Third quarter sales increased 24% over Q2 2022 sales.
Recorded second highest quarterly revenue figure since Q1 2020. Same period sales for Q3 2021 totaled approximately $301K.
Net loss for the nine months ended Sep 30, 2022, of $2.64 million, a 60% improvement over net loss for the nine months ended Sep 30, 2021.
Approximately $900K in net financing used to expedite development of the new WellnessPro Infinity™ Flagship Device.
Increased distributors and clinics to drive wider market footprint and bolster sales volume.
Finalized fixed cost investment to secure key components and avoid supply chain bottlenecks,
Settled negotiations, factory ready for expanded production and negotiated more favorable pricing and terms from suppliers.
The Company also noted that selling, general and administrative expenses increased 23% during the quarter as compared to the quarter ended September 30, 2021. The increase is primarily due to increases in sales and marketing, payroll related, consulting and professional fees and other operating expenses, including the hiring of a new sales director, setting the stage for aggressive sales growth following the expected commercial launch of the WellnessPro Infinity™ device early next year.
“As we have said, the WellnessPro Infinity™ will set an entirely new standard in the Bioelectronics marketplace,” noted Wolfson. “There’s nothing like it on the market due to strong advances in overall capability, affordability, flexibility, ease of use, and a revolutionary doctor-patient interface. We believe this will be far and away the most advanced and most effective electrotherapy device to ever hit the market.”
The NEW WellnessPro Infinity™ device features:
One compact device encompassing ALL electrotherapy modalities, producing any frequency, any wave form (typical or atypical), and any level of modulation.
Support for TENS, Microcurrent, IF, EMS, PEMF, CES, VNS, PNS, COLD Laser, POD Synchronization, IDNA™, Deep Pluse™, Cloud access and much more.
Unprecedented accuracy.
An ease of use that we believe is better than any electrotherapy device on the market.
A New Doctor-Patient Portal for updates and personalized treatments.
The Company looks forward to continued onboarding of new sales representatives and clinics to expand and expedite the WellnessPro Infinity’s™ market penetration. Trade shows will continue to represent a key component of this strategy. Another marketing strategy will be to reach out to past customers that have purchased approximately 10,000 + total legacy units over the last decade to offer them the opportunity to reorder the new and improved WellnessPro Infinity™. We expect our past customers will preorder new units which will result in significant projected income. The preorder campaign in advance of shipment will help to expedite cashflow for the Company and provide expected working capital for inventory and debt settlement.
Wolfson added, “We look forward to an exciting period ahead. Development of the Infinity device concluded on schedule and we are now in the homestretch before an expected commercial launch early in 2023. POD development is going as planned and we look forward to sharing progress in our upcoming press releases soon. Our goal is to go to market with the WellnessPro Infinity™ first, then release the POD upon FDA 510k clearance shortly after.”
The Company has primarily utilized convertible note financing to support the growth of the business. These notes are all convertible at a fixed price as the Company was able to successfully settle all convertible notes and warrants that have variable discounts. Upon reaching its projected revenue targets for the new Wellness Pro Infinity next year, the Company expects to obtain substantial institutional financing and commence the steps needed to uplist to a major exchange.
The Company is in the process of refinancing the commercial building that it owns. The building is recorded as a fixed asset on the balance sheet with a cost of $875K and a corresponding mortgage liability of $526K as of September 30, 2022. However, the current appraised value of the building is over $1.5M, resulting in net equity of over $1M. The Company is in the process of negotiating a sale-leaseback of the property with favorable lease terms in order to possibly obtain over $1M in net cash after the transaction. The Company has a sufficient net loss carryforward that it expects that none of this gain will result in taxable income. Consequently, it expects to use the proceeds to retire convertible debt that has dilutive features and working growth capital.
About Electromedical Technologies
Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company’s goal is to reduce pain and improve overall human wellbeing. The Company’s current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.
For more information, please visit www.electromedtech.com.
Note: Nonhuman preliminary studies that we are planning to start in the near future and their applications are not related to our current product in any way and are currently not cleared in the US.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
Corporate Contact:
Electromedical Technologies, Inc.
Tel: 1.888.880.7888
Email: ir@electromedtech.com
https://electromedtech.com
Public Relations:
EDM Media, LLC
https://edm.media
View original content:https://www.prnewswire.com/news-releases/electromedical-technologies-announces-financial-and-operational-highlights-for-the-three-and-nine-months-ended-september-30-2022-301694556.html
SOURCE Electromedical Technologies, Inc.
Related Quotes
Prof Juerg Matter of Southampton University says the award was recognition of 15 years of research.
Nio (NYSE: NIO) stock spiked Monday morning, but it didn't take long for it to reverse course. The volatility shows just how dynamic the economic situation is in China. Shares of the Chinese EV maker jumped nearly 7% after the market opened, but by 12:40 p.m. ET, Nio stock was down by 1.6%.
Have an issue with your financial adviser or looking for a new one? Email questions and concerns to picks@marketwatch.com.
DEEP DIVE Stocks of companies that raise dividends consistently have outperformed during this year’s bear market. Below is a screen showing which stocks are analysts’ favorites for next year among an expanded list of Dividend Aristocrats.
A roundup of recent banking and finance news across Greater Philadelphia: A coalition of 13 Republican state attorneys general wants to stop Vanguard Group from buying shares in U.S. utilities companies due to the investment manager’s environmental, social and governance policies. The attorneys general filed a motion last week to the Federal Energy Regulatory Commission requesting it block Vanguard’s purchase.
Shares of enterprise software giants Snowflake (NYSE: SNOW), Datadog (NASDAQ: DDOG), and MongoDB (NASDAQ: MDB) were plunging on Monday, down by 8.7%, 6.4%, and 9.4%, respectively, as of 3:06 p.m. ET. There wasn't much company-specific news today, although Snowflake reported earnings last week, and MongoDB will report tomorrow. Friday's strong jobs and wages report, combined with today's stronger-than-expected services Purchasing Managers' Index (PMI) reading, showed the economy may be stronger than generally thought — surprising, especially since recent financial results and guidance in the software industry have been less than stellar.
Yahoo Finance Live looks at cannabis-tied shares following President Biden's signing of a marijuana research bill.
In this article, we will discuss the 12 best undervalued energy stocks to buy. If you want to explore similar stocks, you can also take a look at 5 Best Undervalued Energy Stocks to Buy. 2022 has been the year for energy stocks. While all sectors of the economy fluctuated, the energy sector remained relatively […]
Shares of small- and mid-cap Chinese stocks including Tuya (NYSE: TUYA), EHang (NASDAQ: EH), and Lufax (NYSE: LU) were moving higher today after China again took another step away from its zero-COVID policy, boosting investor confidence that the economy would fully reopen in the coming months. Over the weekend, Beijing and Shenzhen announced that they would lift requirements that commuters show negative COVID tests before travel.
KeyBanc Capital Markets sees "clear signs" of an inventory correction cycle, and think the correction is "largely priced in."
Many people wonder whether they should be investing in qualified or non-qualified dividends and what the differences are. The largest difference is in how each is taxed. To help you determine what stock paying dividends could have a place in … Continue reading → The post Qualified vs. Non-Qualified Dividends appeared first on SmartAsset Blog.
On top of strong dividend growth, all three stocks have displayed remarkable relative strength in 2022, outperforming the general market handily.
Elon Musk's group and its Chinese rivals are often among the choices of investors betting on electric vehicles.
In this article, we will take a look at the 11 best quality stocks to buy now. If you want to see more stocks in this selection, go to the 5 Best Quality Stocks to Buy Now. During these uncertain times, when the Federal Reserve is on a mission to fight inflation by increasing benchmark […]
With a yield of 9.62%, the recently expired Series I bond was understandably popular. With interest rates rising, bond funds are down this year and banks continue to offer miserly rates on deposit accounts. So it's no wonder that a … Continue reading → The post It Pays to Procrastinate: The New 6.89% I bonds Will Beat the Old 9.62% Bonds in Just 4 Years appeared first on SmartAsset Blog.
(Bloomberg) — There’s a hidden risk to the global financial system embedded in the $65 trillion of dollar debt being held by non-US institutions via currency derivatives, according to the Bank for International Settlements. Most Read from Bloomberg‘Huge, Missing and Growing:’ $65 Trillion in Dollar Debt Sparks ConcernStocks Hit by Fed-Hike Jitters as US Yields Surge: Markets WrapElon Musk’s Impossible Electric Truck Is Getting the Last LaughAmbitious Plans to Build Indonesia a Brand New Capital
Despite the soft economic backdrop, 2022 has still provided several large-scale takeovers. Microsoft’s acquisition of Activision Blizzard ($68.7 billion – expected to close next year), Broadcom’s of VMWare (~$61 billion – by the end of next year, too) and Oracle’s of Cerner ($28.3 billion), are all notable deals that readily come to mind. For companies, a lot of the time, larger is preferable; smaller businesses can take advantage of cost-savings that larger organizations have, while bigger enti
After a punishing 2022, it may be time to bet on bonds backed by the U.S. government, particularly if a recession hits, according to Truist Advisory Services.
As investors begin to see light at the end of the Federal Reserve rate-hike tunnel, real estate investment trusts (REITs) are bouncing back off their lows of six weeks ago. Now could be an ideal time to start building a basket of REIT stocks. But with 208 REITs to choose from, how does an investor know which ones make the best purchases? Take a look at five well-established REITs from diversified subsectors that have high-quality, long-term total returns (appreciation plus nonreinvested dividend
Over the last year, a good number of insiders have significantly increased their holdings in SoFi Technologies, Inc…